Abstract
Francisella tularensis is the causative agent of tularaemia, a disease which occurs naturally in some countries in the northern hemisphere. Recently, there has been a high level of interest in devising vaccines against the bacterium because of the potential for it to be used as a bioterrorism agent. Previous human volunteer studies have shown that a strain of F. tularensis [the live vaccine strain (LVS)] that has been attenuated by laboratory passage is effective in humans as a vaccine against airborne disease. However, for a variety of reasons it seems unlikely that the LVS strain will be licensed for use in humans. Against this background there is an effort to devise a licensable vaccine against tularaemia. The prospects for a killed whole-cell subunit of live attenuated vaccine are reviewed. A rationally attenuated mutant seems the most likely route to a new tularaemia vaccine. © 2007 Federation of European Microbiological Societies.
Author supplied keywords
Cite
CITATION STYLE
Griffin, K. F., Oyston, P. C. F., & Titball, R. W. (2007, April). Francisella tularensis vaccines. FEMS Immunology and Medical Microbiology. https://doi.org/10.1111/j.1574-695X.2007.00219.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.